Inventor
WONG LILLY L
US11 patents
⚠️ This page may combine multiple inventors who share the name “WONG LILLY L”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
CELGENE CORP
10 patentsUS10357489B2Jul 23, 2019
Antiproliferative compounds and methods of use thereof
CELGENE CORP20 citations92
US11185543B2Nov 30, 2021
Antiproliferative compounds and methods of use thereof
CELGENE CORP5 citations82
US10969381B2Apr 6, 2021
Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile
CELGENE CORP1 citations72
US11726080B2Aug 15, 2023
Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile
CELGENE CORP1 citations71
US11660297B2May 30, 2023
Antiproliferative compounds and second active agents for combined use
CELGENE CORP2 citations71
US12510533B2Dec 30, 2025
Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile
CELGENE CORP0 citations61
US12053466B2Aug 6, 2024
Antiproliferative compounds and bispecific antibody against BCMA and CD3 for combined use
CELGENE CORP0 citations61
US11439637B2Sep 13, 2022
Antiproliferative compounds and bispecific antibody against BCMA and CD3 for combined use
CELGENE CORP0 citations61
US12186311B2Jan 7, 2025
Antiproliferative compounds and second active agents for combined use
CELGENE CORP0 citations60
US12029738B2Jul 9, 2024
Antiproliferative compounds and methods of use thereof
CELGENE CORP0 citations59